ABSTRACT
PURPOSE: The partial ineffectiveness and side effects of inflammatory bowel disease (IBD) current therapies drive basic research to look for new therapeutic target in order to develop new drug lead. Considering the pivotal role played by toll-like receptors (TLRs) in gut inflammation, we evaluate here the therapeutic effect of the synthetic glycolipid TLR4 antagonist FP7. METHODS: The anti-inflammatory effect of FP7, active as TLR4 antagonist, was evaluated on peripheral blood mononuclear cells (PBMCs) and lamina propria mononuclear cells (LPMCs) isolated from IBD patients, and in a mouse model of ulcerative colitis. RESULTS: FP7 strongly reduced the inflammatory responses induced by lipopolysaccharide (LPS) in vitro, due to its capacity to compete with LPS for the binding of TLR4/MD-2 receptor complex thus inhibiting both the MyD88- and TRIF-dependent inflammatory pathways. Colitic mice treated with FP7 exhibit reduced colonic inflammation and decreased levels of pro-inflammatory cytokines. CONCLUSIONS: This study suggests that TLR4 chemical modulation can be an effective therapeutic approach to IBD. The selectivity of FP7 on TLR4 makes this molecule a promising drug lead for new small molecules-based treatments.
Subject(s)
Colitis, Ulcerative/drug therapy , Glycolipids/therapeutic use , Toll-Like Receptor 4/metabolism , Adult , Animals , Cells, Cultured , Colitis, Ulcerative/metabolism , Colon/drug effects , Colon/metabolism , Cytokines/metabolism , Disease Models, Animal , Female , Humans , Inflammation/drug therapy , Inflammation/metabolism , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/metabolism , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Male , Mice , Middle Aged , Young AdultABSTRACT
Modern adjuvants for vaccine formulations are immunostimulating agents whose action is based on the activation of pattern recognition receptors (PRRs) by well-defined ligands to boost innate and adaptive immune responses. Monophosphoryl lipid A (MPLA), a detoxified analogue of lipid A, is a clinically approved adjuvant that stimulates toll-like receptor 4 (TLR4). The synthesis of MPLA poses manufacturing and quality assessment challenges. Bridging this gap, we report here the development and preclinical testing of chemically simplified TLR4 agonists that could sustainably be produced in high purity and on a large scale. Underpinned by computational and biological experiments, we show that synthetic monosaccharide-based molecules (FP compounds) bind to the TLR4/MD-2 dimer with submicromolar affinities stabilizing the active receptor conformation. This results in the activation of MyD88- and TRIF-dependent TLR4 signaling and the NLRP3 inflammasome. FP compounds lack in vivo toxicity and exhibit adjuvant activity by stimulating antibody responses with a potency comparable to MPLA.
Subject(s)
Adjuvants, Immunologic/pharmacology , Glucosamine/pharmacology , Glycolipids/pharmacology , Toll-Like Receptor 4/antagonists & inhibitors , Adaptor Proteins, Vesicular Transport/metabolism , Adjuvants, Immunologic/chemical synthesis , Adjuvants, Immunologic/metabolism , Adjuvants, Immunologic/toxicity , Animals , Female , Glucosamine/chemical synthesis , Glucosamine/metabolism , Glucosamine/toxicity , Glycolipids/chemical synthesis , Glycolipids/metabolism , Glycolipids/toxicity , Humans , Inflammasomes/metabolism , Interleukin-1/metabolism , Macrophages/drug effects , Mice, Inbred C57BL , Myeloid Differentiation Factor 88/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Signal Transduction/drug effects , Toll-Like Receptor 4/metabolismABSTRACT
This study examines the effect of co-administration of antimicrobial peptides and the synthetic glycolipid FP7, which is active in inhibiting inflammatory cytokine production caused by TLR4 activation and signaling. The co-administration of two lipopolysaccharide (LPS)-neutralizing peptides (a cecropinâ A-melittin hybrid peptide and a human cathelicidin) enhances by an order of magnitude the potency of FP7 in blocking the TLR4 signal. Interestingly, this is not an additional effect of LPS neutralization by peptides, because it also occurs if cells are stimulated by the plant lectin phytohemagglutinin, a non-LPS TLR4 agonist. Our data suggest a dual mechanism of action for the peptides, not exclusively based on LPS binding and neutralization, but also on a direct effect on the LPS-binding proteins of the TLR4 receptor complex. NMR experiments in solution show that peptide addition changes the aggregation state of FP7, promoting the formation of larger micelles. These results suggest a relationship between the aggregation state of lipidâ A-like ligands and the type and intensity of the TLR4 response.
Subject(s)
Antimicrobial Cationic Peptides/chemistry , Glycolipids/chemistry , Melitten/chemistry , Toll-Like Receptor 4/antagonists & inhibitors , Acute-Phase Proteins/metabolism , Antimicrobial Cationic Peptides/pharmacology , Carrier Proteins/metabolism , Cell Line , Cell Survival/drug effects , Glycolipids/pharmacology , Humans , Ligands , Melitten/pharmacology , Membrane Glycoproteins/metabolism , Protein Binding , Protein Conformation , Toll-Like Receptor 4/metabolism , CathelicidinsABSTRACT
The structure-activity relationship was investigated in a series of synthetic TLR4 antagonists formed by a glucosamine core linked to two phosphate esters and two linear carbon chains. Molecular modeling showed that the compounds with 10, 12, and 14 carbons chains are associated with higher stabilization of the MD-2/TLR4 antagonist conformation than in the case of the C16 variant. Binding experiments with human MD-2 showed that the C12 and C14 variants have higher affinity than C10, while the C16 variant did not interact with the protein. The molecules, with the exception of the C16 variant, inhibited the LPS-stimulated TLR4 signal in human and murine cells, and the antagonist potency mirrored the MD-2 affinity calculated from in vitro binding experiments. Fourier-transform infrared, nuclear magnetic resonance, and small angle X-ray scattering measurements suggested that the aggregation state in aqueous solution depends on fatty acid chain lengths and that this property can influence TLR4 activity in this series of compounds.